SynthesisPloS one2019
Risk factors associated with IgA vasculitis with nephritis (Henoch-Schönlein purpura nephritis) progressing to unfavorable outcomes: A meta-analysis.
Synthesis in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Guidelines for the diagnosis and management of childhood immunoglobulin A vasculitis.World journal of pediatrics : WJP · 2025Guideline
- National recommendations for the management of children and young people with IgA vasculitis: a best available evidence, group agreement-based approach.Archives of disease in childhood · 2024Guideline
- Trial
- Clinical, laboratory, and pathological correlates of crescent formation in biopsy-proven pediatric IgA vasculitis nephritis.Pediatric nephrology (Berlin, Germany) · 2026Article
- Biomarkers of kidney involvement in paediatric IgA vasculitis: a systematic review and meta-analysis.Pediatric nephrology (Berlin, Germany) · 2026Review
- Efficacy and safety of telitacicept in IgA vasculitis nephritis: a single-center retrospective study.European journal of pediatrics · 2026Article
- A Pathway to High Quality Clinical Trials in IgA Vasculitis Nephritis: Meeting Proceedings From a Multiprofessional International Collaborative Workshop.Kidney international reports · 2026Article
- An individualized prognostic nomogram integrating clinical and pathological features in pediatric IgA vasculitis nephritis.Frontiers in medicine · 2026Article
- Risk Factors of Histopathological Crescent Formation in Pediatric IgA Vasculitis Nephritis.Medicina (Kaunas, Lithuania) · 2025Article
- Telitacicept as a BAFF/APRIL dual inhibitor: efficacy and safety in reducing proteinuria for refractory childhood IgA vasculitis nephritis.Pediatric nephrology (Berlin, Germany) · 2025Observational
- Tonsillectomy in Immunoglobulin A vasculitis with nephritis: case series.CEN case reports · 2025Article
- Modern biomarkers in IgA vasculitis with nephritis in children.Central-European journal of immunology · 2025Review
- Differences of clinicopathological characteristics and outcomes of IgA nephropathy patients with and without nephrotic syndrome.International urology and nephrology · 2024Article
- Overview of childhood vasculitis.Journal of rheumatic diseases · 2024Review
- [Urinary protein and renal pathological features in children with immunoglobulin A vasculitis with nephritis and hypercoagulability].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024Article
- Long-term outcome of combination therapy with corticosteroids, mizoribine and RAS inhibitors as initial therapy for severe childhood IgA vasculitis with nephritis.Pediatric nephrology (Berlin, Germany) · 2023Article
- Clinical course and management of children with IgA vasculitis with nephritis.Pediatric nephrology (Berlin, Germany) · 2023Observational
- Article
- A case series on recurrent and persisting IgA vasculitis (Henoch Schonlein purpura) in children.Pediatric rheumatology online journal · 2023Article
- ASSOCIATION BETWEEN HIGH MOBILITY GROUP BOX 1 PROTEIN GENE (rs41369348) POLYMORPHISM AND IMMUNOGLOBULIN A VASCULITIS IN CHILDREN.Acta clinica Croatica · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify risk factors associated with unfavorable outcomes in children with IgA vasculitis with nephritis (Henoch-Schőnlein purpura nephritis)(IgA-VN).
methodsPubMed, Embase, and Web of Science databases were searched for studies, published in English through February 2019. The data were extracted to perform pooled analysis, heterogeneity testing, subgroup analysis, sensitivity analysis, and publication bias analysis.
resultsThis meta-analysis showed that, older age at onset (WMD 1.77, 95% CI 0.35-3.18, p = 0.014), lower glomerular filtration rate (GFR; WMD -23.93, 95% CI -33.78- -14.09, p<0.0001), initial renal manifestations with nephrotic syndrome (OR 1.74, 95% CI 1.12-2.70, p = 0.013), with nephritic-nephrotic syndrome (OR 4.55, 95% CI 2.89-7.15, p<0.0001) and renal biopsy with crescentic nephritis (International Study of Kidney Disease in Children [ISKDC] grades III-V) (OR 3.85, 95% CI 2.37-6.28, p<0.0001) were significant risk factors associated with poor outcomes in IgA-VN, whereas initial clinical features with hematuria (OR 0.33, 95% CI 0.16-0.69, p = 0.003) and mild proteinuria±hematuria (OR 0.46, 95% CI 0.28-0.75, p<0.0001) were associated with progression to good outcomes. By contrast, gender, hypertension and initial renal manifestations of acute nephritic syndrome were not significantly associated with poor outcomes in IgA-VN.
conclusionThis meta-analysis showed that older age at onset, lower GFR, initial renal features of nephrotic syndrome and nephritic-nephrotic syndrome and renal biopsy with crescentic nephritis (ISKDC grades III-V) were predictive of poor prognosis in children with IgA-VN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.